- Report
- January 2026
Global
From €4292EUR$4,900USD£3,725GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- January 2026
- 120 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- July 2023
- 284 Pages
Global
From €3153EUR$3,600USD£2,737GBP
Avibactam is a non-β-lactam β-lactamase inhibitor used in combination with antibiotics to treat infections caused by bacteria. It is used in combination with antibiotics to treat infections caused by bacteria that produce certain types of β-lactamases, enzymes that can inactivate certain antibiotics. Avibactam works by blocking the action of these enzymes, allowing the antibiotic to work more effectively. Avibactam is used in combination with antibiotics to treat a variety of infections, including urinary tract infections, skin and soft tissue infections, and pneumonia.
Avibactam is a relatively new class of antibiotics, and is currently used in combination with other antibiotics to treat a variety of infections. It is an important tool in the fight against antibiotic resistance, as it helps to prevent bacteria from becoming resistant to antibiotics.
Some companies in the Avibactam market include AstraZeneca, Merck, Pfizer, and Allergan. Show Less Read more